GSDME and ovarian carcinoma: In conclusion, the small molecule drug BI 2536 was verified to inhibit the proliferation of ovarian cancer cells and induce concurrent apoptosis and pyroptosis through the caspase-3/GSDME pathway, and it showed both in vitro and in vivo antitumoral activity and the ability to accumulate CD8+ T cells in tumor sites.